title: [Safety and efficacy evaluation of gemcitabine combined with oxaliplatin for the treatment of patients with lymphoma].
abstract: OBJECTIVE
  To investigate the short-term efficacy and safety of GEMOX regimen for the treatment of lymphoma, so as to provide the reference for further rational selection of chemotherapy.
  
  
  METHODS
  A total of 61 patients with relapse and refractory non-Hodgkin's lymphoma (NHL) treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed.
  
  
  RESULTS
  The improved rate of B symptom was 86.36%; the LDH level in 38 cases with high LDH level after chemotherapy all obviously decreased; the ORR and CBR in 64 patients after treatment were 68.75% and 87.50% respectively; the comparison of ORR and CBR between patients with different IPI score showed significantly statistical difference (P<0.05). The adverse reactions mainly observed in blood and digestive tract, but were mild; adverse reactions were reduced or disappeared after stoping drugs or symptomatic treatment. The median progression-free survival time of patients was 10.5 months.
  
  
  CONCLUSIONS
  Gemcitabine combined with oxaliplatin for treatment of relapse-refractory lymphoma shows singnificant efficacy and low toxicity, this regimen can be used as a second-line chemotheray in clinic.
authors.affiliation: Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China.
authors.forename: Bi-Ling
authors.initials: BL
authors.lastname: Chen
authors.affiliation: Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China.
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China.
authors.forename: Shi-Hai
authors.initials: SH
authors.lastname: Qin
authors.affiliation: Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China.
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China. E-mail: tangqingling1972@126.com.
authors.forename: Qing-Ling
authors.initials: QL
authors.lastname: Tan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D003841:Deoxycytidine / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine